YU71303A - Kombinacija kombrestatina i anti-kancer agensa - Google Patents

Kombinacija kombrestatina i anti-kancer agensa

Info

Publication number
YU71303A
YU71303A YU71303A YUP71303A YU71303A YU 71303 A YU71303 A YU 71303A YU 71303 A YU71303 A YU 71303A YU P71303 A YUP71303 A YU P71303A YU 71303 A YU71303 A YU 71303A
Authority
YU
Yugoslavia
Prior art keywords
combination
combrestatin
anticancer agents
epidophylloptoxins
taxanes
Prior art date
Application number
YU71303A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Priority to MEP-162/08A priority Critical patent/MEP16208A/xx
Publication of YU71303A publication Critical patent/YU71303A/sh
Publication of RS50682B publication Critical patent/RS50682B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Anti-tumor kombinacija koja sadži derivate stillbena i anti-kancer jedinjenja odabranog iz grupe koju čine taksani, agensi za alkiliranje, antimetaboliti, vinca alkaloidi, apidofiloptoksini i antibiotici. Takođe su opisane metode za korišćenje ovih farmaceutskih preparata u lečenju čvrstih karcinoma i slično.[An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, epidophylloptoxins,and antibiotics as the active ingredients is provided. There are also provided methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like.
YUP-713/03A 2001-03-15 2002-03-15 Kombinacija kombrestatina i anti-kancer agensa RS50682B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-162/08A MEP16208A (en) 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15

Publications (2)

Publication Number Publication Date
YU71303A true YU71303A (sh) 2006-08-17
RS50682B RS50682B (sr) 2010-06-30

Family

ID=23053164

Country Status (38)

Country Link
US (4) US20020183266A1 (sh)
EP (1) EP1439839B8 (sh)
JP (1) JP4991107B2 (sh)
KR (1) KR100849610B1 (sh)
CN (2) CN1290504C (sh)
AR (1) AR032989A1 (sh)
AT (1) ATE433750T1 (sh)
AU (1) AU2002304574B2 (sh)
BR (1) BR0208017A (sh)
CA (2) CA2673449C (sh)
CY (1) CY1109364T1 (sh)
CZ (1) CZ302451B6 (sh)
DE (1) DE60232673D1 (sh)
DK (1) DK1439839T3 (sh)
EA (1) EA006316B1 (sh)
EC (1) ECSP034766A (sh)
ES (1) ES2327617T3 (sh)
HK (1) HK1067039A1 (sh)
HR (1) HRPK20030734B3 (sh)
HU (1) HU228510B1 (sh)
IL (2) IL157891A0 (sh)
MA (1) MA27000A1 (sh)
ME (2) MEP16208A (sh)
MX (1) MXPA03007552A (sh)
NO (1) NO332661B1 (sh)
NZ (1) NZ527526A (sh)
PE (1) PE20020909A1 (sh)
PL (1) PL205728B1 (sh)
PT (1) PT1439839E (sh)
RS (1) RS50682B (sh)
SI (1) SI1439839T1 (sh)
SK (1) SK287908B6 (sh)
TN (1) TNSN03060A1 (sh)
TW (1) TWI306028B (sh)
UA (1) UA75127C2 (sh)
UY (1) UY27208A1 (sh)
WO (2) WO2004037258A1 (sh)
ZA (1) ZA200306789B (sh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4470321B2 (ja) 1998-04-03 2010-06-02 味の素株式会社 抗腫瘍剤
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
US20090192098A1 (en) * 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
KR20130088753A (ko) 2010-06-18 2013-08-08 사노피 옴브라불린, 탁산 유도체 및 백금 유도체를 포함하는 항종양 조합물
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
JP4470321B2 (ja) * 1998-04-03 2010-06-02 味の素株式会社 抗腫瘍剤
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
AU1602902A (en) * 2000-10-27 2002-05-06 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2002056692A1 (en) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
SK287908B6 (sk) 2012-03-02
NO20034022D0 (no) 2003-09-11
CN1290504C (zh) 2006-12-20
DK1439839T3 (da) 2009-10-05
CA2673449A1 (en) 2004-05-06
CN1935134B (zh) 2010-12-15
JP4991107B2 (ja) 2012-08-01
WO2002074229A2 (en) 2002-09-26
TWI306028B (en) 2009-02-11
DE60232673D1 (de) 2009-07-30
AU2002304574B2 (en) 2005-09-15
ATE433750T1 (de) 2009-07-15
NO332661B1 (no) 2012-11-26
TNSN03060A1 (en) 2005-12-23
EA200301015A1 (ru) 2004-08-26
AR032989A1 (es) 2003-12-03
MXPA03007552A (es) 2004-10-15
EP1439839B1 (en) 2009-06-17
CN1935134A (zh) 2007-03-28
SI1439839T1 (sl) 2011-09-30
PT1439839E (pt) 2009-09-03
HK1067039A1 (en) 2005-04-01
US20020183266A1 (en) 2002-12-05
PL374406A1 (en) 2005-10-17
WO2004037258A1 (en) 2004-05-06
CA2673449C (en) 2011-10-18
CY1109364T1 (el) 2014-07-02
PE20020909A1 (es) 2002-12-09
US6933320B2 (en) 2005-08-23
JP2005522527A (ja) 2005-07-28
UA75127C2 (en) 2006-03-15
SK11552003A3 (sk) 2004-03-02
BR0208017A (pt) 2004-12-07
IL157891A0 (en) 2004-03-28
US20030060429A1 (en) 2003-03-27
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
ZA200306789B (en) 2005-02-23
HRPK20030734B3 (en) 2006-11-30
EA006316B1 (ru) 2005-10-27
ECSP034766A (es) 2003-10-28
KR100849610B1 (ko) 2008-07-31
CA2470484A1 (en) 2004-05-06
ES2327617T3 (es) 2009-11-02
UY27208A1 (es) 2002-08-30
US20070149476A1 (en) 2007-06-28
ME00056B (me) 2010-06-10
NZ527526A (en) 2006-11-30
HU228510B1 (en) 2013-03-28
HUP0600233A2 (en) 2008-06-30
HUP0600233A3 (en) 2010-03-29
IL157891A (en) 2010-06-16
NO20034022L (no) 2003-09-11
CA2470484C (en) 2009-10-13
EP1439839A1 (en) 2004-07-28
CZ20032476A3 (en) 2004-07-14
MEP16208A (en) 2010-06-10
AU2002304574A1 (en) 2004-05-13
KR20040067866A (ko) 2004-07-30
US20050075295A1 (en) 2005-04-07
MA27000A1 (fr) 2004-12-20
EP1439839B8 (en) 2010-09-01
CZ302451B6 (cs) 2011-05-25
HRP20030734A2 (en) 2005-06-30
CN1547471A (zh) 2004-11-17

Similar Documents

Publication Publication Date Title
YU71303A (sh) Kombinacija kombrestatina i anti-kancer agensa
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
AU7031500A (en) Therapeutic quinazoline compounds
DE60112609D1 (en) Pyrazolopyridine
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
PL367682A1 (en) Dolastatin 10 derivatives
DK1200412T3 (da) Antiproliferative imidazolforbindelser
AU5669198A (en) Cyclosporin derivative, its preparation and pharmaceutical compositions containing same
AU2002239348A1 (en) Pyrazolopyridine derivatives
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AU4170197A (en) Pharmaceutical compounds
AU2002352708A1 (en) Cytotoxic agents
GB9907571D0 (en) Compounds
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AU1469097A (en) Pharmaceutical compounds
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
BG102318A (en) Epoxy-azetidinons, their preparation and application